GR3031618T3 - Orphan receptor - Google Patents

Orphan receptor

Info

Publication number
GR3031618T3
GR3031618T3 GR990402716T GR990402716T GR3031618T3 GR 3031618 T3 GR3031618 T3 GR 3031618T3 GR 990402716 T GR990402716 T GR 990402716T GR 990402716 T GR990402716 T GR 990402716T GR 3031618 T3 GR3031618 T3 GR 3031618T3
Authority
GR
Greece
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
GR990402716T
Other languages
English (en)
Inventor
George G J M Kuiper
Eva Enmark
Jan-Ake Gustafsson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3031618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karobio Ab filed Critical Karobio Ab
Publication of GR3031618T3 publication Critical patent/GR3031618T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GR990402716T 1995-09-08 1999-10-26 Orphan receptor GR3031618T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
PCT/EP1996/003933 WO1997009348A2 (en) 1995-09-08 1996-09-09 Orphan receptor

Publications (1)

Publication Number Publication Date
GR3031618T3 true GR3031618T3 (en) 2000-01-31

Family

ID=27451339

Family Applications (2)

Application Number Title Priority Date Filing Date
GR980300029T GR980300029T1 (en) 1995-09-08 1998-04-30 Orphan receptor
GR990402716T GR3031618T3 (en) 1995-09-08 1999-10-26 Orphan receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR980300029T GR980300029T1 (en) 1995-09-08 1998-04-30 Orphan receptor

Country Status (12)

Country Link
US (2) US5958710A (el)
EP (2) EP0792292B2 (el)
JP (4) JP3131649B2 (el)
KR (1) KR100263137B1 (el)
AT (1) ATE183516T1 (el)
AU (1) AU715528B2 (el)
CA (1) CA2201098C (el)
DE (2) DE69603827T3 (el)
DK (1) DK0792292T4 (el)
ES (1) ES2135249T5 (el)
GR (2) GR980300029T1 (el)
WO (1) WO1997009348A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (en) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, a steroid hormone receptor homolog
EP0980386A2 (en) * 1997-06-10 2000-02-23 Karo Bio Ab Estrogen receptor crystals and ligands
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ES2268789T3 (es) * 1997-09-08 2007-03-16 MERCK & CO., INC. Receptor de estrogeno.
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (en) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogen receptors and bone disease
AU4546900A (en) * 1999-04-09 2000-11-14 Karo Bio Ab Estrogen receptors and bone
AU2002247702A1 (en) * 2001-02-09 2002-08-28 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
JP4381810B2 (ja) 2001-11-19 2009-12-09 イーライ リリー アンド カンパニー 選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002353076A1 (en) * 2001-12-07 2003-06-23 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
KR101092349B1 (ko) 2003-02-21 2011-12-09 다우 글로벌 테크놀로지스 엘엘씨 공액 올레핀의 단독중합법 또는 공중합법
DE602004016150D1 (de) 2003-04-21 2008-10-09 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
ES2338119T3 (es) 2003-04-21 2010-05-04 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor-beta de estrogeno.
EP1667955A2 (en) 2003-07-28 2006-06-14 SmithKline Beecham Corporation Cycloalkylidene compounds as modulators of the estrogen receptor
EP1709443A2 (en) * 2003-12-18 2006-10-11 Procognia, Ltd. Method for analyzing a glycomolecule
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
JPH04505012A (ja) * 1989-03-17 1992-09-03 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ ホルモン応答要素組成物およびアッセイ
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
CA2201098A1 (en) 1997-03-13
ES2135249T3 (es) 1999-10-16
US20030113803A1 (en) 2003-06-19
AU715528B2 (en) 2000-02-03
US5958710A (en) 1999-09-28
DK0792292T4 (da) 2009-07-20
CA2201098C (en) 2001-03-27
EP0792292A2 (en) 1997-09-03
WO1997009348A2 (en) 1997-03-13
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
ES2135249T5 (es) 2009-09-10
ATE183516T1 (de) 1999-09-15
AU6988096A (en) 1997-03-27
EP0792292B2 (en) 2009-04-15
WO1997009348A3 (en) 1997-04-24
DK0792292T3 (da) 2000-02-07
JP2002010788A (ja) 2002-01-15
EP0935000A2 (en) 1999-08-11
JP2005204667A (ja) 2005-08-04
EP0792292B1 (en) 1999-08-18
DE69603827T3 (de) 2009-11-05
US7132261B2 (en) 2006-11-07
KR100263137B1 (ko) 2000-08-01
DE69603827T2 (de) 2000-02-24
JP3131649B2 (ja) 2001-02-05
EP0935000A3 (en) 1999-09-08
GR980300029T1 (en) 1998-04-30
JPH11502417A (ja) 1999-03-02
JP2005204666A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
GR980300029T1 (en) Orphan receptor
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
BG103436A (en) Conjugates applicable in the treatment of the prostate gland cancer
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
AU6045398A (en) Androgen synthesis inhibitors
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
IL142132A0 (en) Methods and compositions for treating receptor mediated diseases
EP1955700A3 (en) Therapeutic treatment of androgen receptor driven conditions
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
PL328858A1 (en) Immunogenous peptides
EP1418235A3 (en) Intracellular domain of the her-2/neu protein for prevention or treatment of maligancies
BR9811264A (pt) Composições imunogênicas ao receptor de gastrina/cck-b e métodos para o tratamento de tumores
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
AP9801269A0 (en) Prostaglandin agonists.
EP1009755A4 (en) STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME
MY122278A (en) 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
BG103286A (en) Compositions and methods for ore dressing
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
AU6633694A (en) Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides
WO2005027833A3 (en) Compound and method for treating androgen-independent prostate cancer
BG103472A (en) Polypeptides encoded by a human lipase-like gene, compositions and methods
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
IL132094A0 (en) Methods and compositions for treatment of ovarian cancer
CA2340475A1 (en) Orphan receptor